New Zealand Dollar trades sideways after mixed China data, three-year high US inflation
NZD/USD trades around 0.5815 at the time of writing on Wednesday, little changed on the day, as investors digest a series of macroeconomic releases from China and the United States (US).
The pair remains broadly stable following Chinese data released during the Asian session. According to the National Bureau of Statistics of China, the Consumer Price Index (CPI) declined by 0.1% MoM in May, compared with a 0.3% increase previously. Meanwhile, the Producer Price Index (PPI) rose by 3.9% YoY, above market expectations of a 3.8% increase. These mixed figures failed to provide meaningful support to the New Zealand Dollar (NZD), which is often viewed as sensitive to developments in the Chinese economy.
Market attention has now shifted to the United States, where inflation continues to accelerate. Data released on Wednesday showed that the CPI increased by 4.2% YoY in May, up from 3.8% in April and in line with market expectations. On a monthly basis, inflation rose by 0.5%, also matching consensus forecasts.
The core CPI, which excludes food and energy prices, increased by 0.2% MoM and 2.9% YoY. This underlying inflation measure remains closely watched by policymakers as a gauge of persistent price pressures.
Despite the stronger yearly inflation reading, the reaction in currency markets has remained limited. The US Dollar (USD) has struggled to post a meaningful move following the release, as investors await further clarity on the next policy steps from the Federal Reserve (Fed). Against this backdrop, NZD/USD continues to trade sideways around 0.5815 as market participants assess the potential implications of the inflation data for the US interest rate outlook.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash

25 Days, Four Launches in Sight! Rocket Lab (RKLB.US) Accelerates Rocket Launches to Advance Its Ambitious "Space AI Infrastructure" Goals
After another successful mission, Rocket Lab's 97th Electron rocket is now positioned at the launch pad. This flight will be Rocket Lab's fourth launch in 25 days and its 18th launch in 2026.
